Is Src a viable target for treating solid tumours?

Current Cancer Drug Targets

Volumn 10, Issue 7, 2010, Pages 683-694

  Elsberger, B ^a   Stewart, B ^a   Tatarov, O ^a   Edwards, J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Proto oncogene; Src; Targeted therapy; Tyrosine kinase

Indexed keywords

BOSUTINIB; CARBOPLATIN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CYCLIN A; CYCLIN D1; CYCLIN E; DASATINIB; DOCETAXEL; EXEMESTANE; FIBROBLAST GROWTH FACTOR; FULVESTRANT; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NILUTAMIDE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; UROKINASE RECEPTOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANOIKIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOKINE RELEASE; ESOPHAGUS CANCER; EXTRACELLULAR MATRIX; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOSARCOMA; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; NONHUMAN; ONCOGENE SRC; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; SALIVARY GLAND CANCER; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; UTERINE TUBE CARCINOMA;

EID: 78649261432     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910793605802     Document Type: Article

References (112)

1. Rous, P. A sarcoma of the fowl transmissible by an agent separable for the tumor cells. J. Exp. Med. 1911, 13, 397-411.
2. Martin, G. S. Rous sarcoma virus: a function required for the maintenance of the transformed state. Nature 1970, 227, 1021-1023.
3. Stehelin, D.; Varmus, H. E.; Bishop, J. M.; Vogt, P. K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976, 260, 170-173.
4. Ly, Q. P.; Yeatman, T. J. Clinical relevance of targeted interference with Src-mediated signal transduction events. Recent Results Cancer Res. 2007, 172, 169-188.
5. Cooper, J. A.; Howell, B. The when and how of Src regulation. Cell 1993, 73, 1051-1054.
6. Roskoski, R., Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem. Biophys. Res. Commun. 2005, 331, 1-14.
7. Stover, D. R.; Furet, P.; Lydon, N. B. Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain. J. Biol. Chem. 1996, 271, 12481-12487.
8. Mayer, B. J. SH3 domains: complexity in moderation. J. Cell Sci. 2001,114, 1253-1263.
9. Yeatman, T. J. A renaissance for SRC. Nat. Rev. Cancer 2004, 4, 470-480.
10. Elsberger, B.; Tan, B. A.; Mitchell, T. J.; Brown, S. B.; Mallon, E. A.; Tovey, S. M.; Cooke, T. G.; Brunton, V. G.; Edwards, J. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? Am. J. Pathol. 2009, 175, 1389-1397.
11. Jacobs, C.; Rubsamen, H. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res. 1983, 43, 1696-1702.
12. Thomas, S. M.; Brugge, J. S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997, 13, 513-609.
13. Bjorge, J. D.; Jakymiw, A.; Fujita, D. J. Selected glimpses into the activation and function of Src kinase. Oncogene 2000, 19, 5620-5635.
14. Fincham, V. J.; Brunton, V. G.; Frame, M. C. The SH3 domain directs acto-myosin-dependent targeting of v-Src to focal adhesions via phosphatidylinositol 3-kinase. Mol. Cell Biol. 2000, 20, 6518-6536.
15. Levy, J. B.; Iba, H.; Hanafusa, H. Activation of the transforming potential of p60c-src by a single amino acid change. Proc. Natl. Acad. Sci. USA 1986, 83, 4228-4232.
16. Lin, P. H.; Shenoy, S.; Galitski, T.; Shalloway, D. Transformation of mouse cells by wild-type mouse c-Src. Oncogene 1995, 10, 401-405.
17. Chambers, A. F.; Groom, A. C.; MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002,2, 563-572.
18. Boyer, B.; Bourgeois, Y.; Poupon, M. F. Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 2002, 21, 2347-2356.
19. Nakagawa, T.; Tanaka, S.; Suzuki, H.; Takayanagi, H.; Miyazaki, T.; Nakamura, K.; Tsuruo, T. Overexpression of the csk gene suppresses tumor metastasis in vivo. Int. J. Cancer 2000, 88, 384-391.
20. Jallal, H.; Valentino, M. L.; Chen, G.; Boschelli, F.; Ali, S.; Rabbani, S. A. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 2007, 67, 1580-1588.
21. Park, S. I.; Zhang, J.; Phillips, K. A.; Araujo, J. C.; Najjar, A. M.; Volgin, A. Y.; Gelovani, J. G.; Kim, S. J.; Wang, Z.; Gallick, G. E. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008, 68, 3323-3333.
22. Myoui, A.; Nishimura, R.; Williams, P. J.; Hiraga, T.; Tamura, D.; Michigami, T.; Mundy, G. R.; Yoneda, T. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res. 2003,63, 5028-5033.
23. Pichot, C. S.; Hartig, S. M.; Xia, L.; Arvanitis, C.; Monisvais, D.; Lee, F. Y.; Frost, J. A.; Corey, S. J. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br. J. Cancer 2009, 101, 38-47.
24. Riley, D.; Carragher, N. O.; Frame, M. C.; Wyke, J. A. The mechanism of cell cycle regulation by v-Src. Oncogene 2001, 20, 5941-5950.
25. Schlaepfer, D. D.; Hauck, C. R.; Sieg, D. J. Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol. 1999, 71, 435-478.
26. Rajeshkumar, N. V.; Tan, A. C.; De Oliveira, E.; Womack, C.; Wombwell, H.; Morgan, S.; Warren, M. V.; Walker, J.; Green, T. P.; Jimeno, A.; Messersmith, W. A.; Hidalgo, M. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin. Cancer Res. 2009, 15, 4138-4146.
27. Edwards, J.; Krishna, N. S.; Witton, C. J.; Bartlett, J. M. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin. Cancer Res. 2003, 9, 5271-5281.
28. Tatarov, O.; Mitchell, T. J.; Seywright, M.; Leung, H. Y.; Brunton, V. G.; Edwards, J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res. 2009, 15, 3540-3549.
29. Fincham, V. J.; Frame, M. C. The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility. EMBO J. 1998, 17, 81-92.
30. Hynes, R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69, 11-25.
31. Serrels, A.; Timpson, P.; Canel, M.; Schwarz, J. P.; Carragher, N. O.; Frame, M. C.; Brunton, V. G.; Anderson, K. I. Real-time study of E-cadherin and membrane dynamics in living animals: implications for disease modeling and drug development. Cancer Res. 2009,69, 2714-2719.
32. Datta, A.; Huber, F.; Boettiger, D. Phosphorylation of beta3 integrin controls ligand binding strength. J. Biol. Chem. 2002, 277, 3943-3949.
33. Johansson, M. W.; Larsson, E.; Luning, B.; Pasquale, E. B.; Ruoslahti, E. Altered localization and cytoplasmic domain-binding properties of tyrosine-phosphorylated beta 1 integrin. J. Cell Biol. 1994,126, 1299-1309.
34. Cavallaro, U.; Christofori, G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 2004, 4, 118-132.
35. Guo, W.; Giancotti, F. G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004, 5, 816-826.
36. Kanner, S. B.; Reynolds, A. B.; Vines, R. R.; Parsons, J. T. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc. Natl. Acad. Sci. USA 1990, 87, 3328-3332.
37. Weaver, A. M.; Karginov, A. V.; Kinley, A. W.; Weed, S. A.; Li, Y.; Parsons, J. T.; Cooper, J. A. Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr. Biol. 2001,11, 370-374.
38. Huang, C.; Ni, Y.; Wang, T.; Gao, Y.; Haudenschild, C. C.; Zhan, X. Down-regulation of the filamentous actin cross-linking activity of cortactin by Src-mediated tyrosine phosphorylation. J. Biol. Chem. 1997, 272, 13911-13915.
39. Webb, B. A.; Jia, L.; Eves, R.; Mak, A. S. Dissecting the functional domain requirements of cortactin in invadopodia formation. Eur. J. Cell Biol. 2007, 86, 189-206.
40. Chan, K. T.; Cortesio, C. L.; Huttenlocher, A. FAK alters invadopodia and focal adhesion composition and dynamics to regulate breast cancer invasion. J. Cell Biol. 2009, 185, 357-370.
41. Shih, W. L.; Liao, M. H.; Yu, F. L.; Lin, P. Y.; Hsu, H. Y.; Chiu, S. J. AMF/PGI transactivates the MMP-3 gene through the activation of Src-RhoA-phosphatidylinositol 3-kinase signaling to induce hepatoma cell migration. Cancer Lett. 2008, 270, 202-217.
42. Nyalendo, C.; Michaud, M.; Beaulieu, E.; Roghi, C.; Murphy, G.; Gingras, D.; Beliveau, R. Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration. J. Biol. Chem. 2007, 282, 15690-15699.
43. Shin, E. Y.; Ma, E. K.; Kim, C. K.; Kwak, S. J.; Kim, E. G. Src/ERK but not phospholipase D is involved in keratinocyte growth factor-stimulated secretion of matrix metalloprotease-9 and urokinase-type plasminogen activator in SNU-16 human stomach cancer cell. J. Cancer Res. Clin. Oncol. 2002, 128, 596-602.
44. Leupold, J. H.; Asangani, I.; Maurer, G. D.; Lengyel, E.; Post, S.; Allgayer, H. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. Mol. Cancer Res. 2007, 5, 485-496.
45. Lin, B. R.; Chang, C. C.; Chen, L. R.; Wu, M. H.; Wang, M. Y.; Kuo, I. H.; Chu, C. Y.; Chang, K. J.; Lee, P. H.; Chen, W. J.; Kuo, M. L.; Lin, M. T. Cysteine-rich 61 (CCN1) enhances chemotactic migration, transendothelial cell migration, and intravasation by concomitantly up-regulating chemokine receptor 1 and 2. Mol. Cancer Res. 2007, 5, 1111-1123.
46. Criscuoli, M. L.; Nguyen, M.; Eliceiri, B. P. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 2005, 105, 1508-1514.
47. Weis, S.; Cui, J.; Barnes, L.; Cheresh, D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol. 2004, 167, 223-229.
48. Frisch, S. M.; Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 1994, 124, 619-626.
49. Johnson, D.; Agochiya, M.; Samejima, K.; Earnshaw, W.; Frame, M.; Wyke, J. Regulation of both apoptosis and cell survival by the v-Src oncoprotein. Cell Death Differ. 2000, 7, 685-696.
50. Giannoni, E.; Fiaschi, T.; Ramponi, G.; Chiarugi, P. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals. Oncogene 2009,28, 2074-2086.
51. Mukhopadhyay, D.; Tsiokas, L.; Zhou, X. M.; Foster, D.; Brugge, J. S.; Sukhatme, V. P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995,375, 577-581.
52. Cheranov, S. Y.; Karpurapu, M.; Wang, D.; Zhang, B.; Venema, R. C.; Rao, G. N. An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood 2008,111, 5581-5591.
53. Summy, J. M.; Trevino, J. G.; Lesslie, D. P.; Baker, C. H.; Shakespeare, W. C.; Wang, Y.; Sundaramoorthi, R.; Metcalf, C. A. III.; Keats, J. A.; Sawyer, T. K.; Gallick, G. E. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol. Cancer Ther. 2005, 4, 1900-1911.
54. Araujo, J.; Logothetis, C. Targeting Src signaling in metastatic bone disease. Int. J. Cancer 2008, 124, 1-6.
55. Duong, L. T.; Lakkakorpi, P. T.; Nakamura, I.; Machwate, M.; Nagy, R. M.; Rodan, G. A. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. J. Clin. Invest. 1998, 102, 881-892.
56. Soriano, P.; Montgomery, C.; Geske, R.; Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64, 693-702.
57. Roodman, G. D. Mechanisms of bone metastasis. N. Engl. J. Med. 2004,350, 1655-64.
58. Saad, F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int. 2009, 103, 434-440.
59. Zhang, X. H.; Wang, Q.; Gerald, W.; Hudis, C. A.; Norton, L.; Smid, M.; Foekens, J. A.; Massague, J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009,16, 67-78.
60. Kleber, S.; Sancho-Martinez, I.; Wiestler, B.; Beisel, A.; Gieffers, C.; Hill, O.; Thiemann, M.; Mueller, W.; Sykora, J.; Kuhn, A.; Schreglmann, N.; Letellier, E.; Zuliani, C.; Klussmann, S.; Teodorczyk, M.; Grone, H. J.; Ganten, T. M.; Sultmann, H.; Tuttenberg, J.; von Deimling, A.; Regnier-Vigouroux, A.; Herold-Mende, C.; Martin-Villalba, A. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13, 235-248.
61. Posadas, E. M.; Al-Ahmadie, H.; Robinson, V. L.; Jagadeeswaran, R.; Otto, K.; Kasza, K. E.; Tretiakov, M.; Siddiqui, J.; Pienta, K. J.; Stadler, W. M.; Rinker-Schaeffer, C.; Salgia, R. FYN is overexpressed in human prostate cancer. BJU Int. 2009, 103, 171-177.
62. Verbeek, B. S.; Vroom, T. M.; Adriaansen-Slot, S. S.; Ottenhoff-Kalff, A. E.; Geertzema, J. G.; Hennipman, A.; Rijksen, G. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol. 1996, 180, 383-388.
63. Fu, Y.; Zagozdzon, R.; Avraham, R.; Avraham, H. K. CHK negatively regulates Lyn kinase and suppresses pancreatic cancer cell invasion. Int. J. Oncol. 2006, 29, 1453-1458.
64. Mazurenko, N. N.; Kogan, E. A.; Zborovskaya, I. B.; Kisseljov, F. L. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur. J. Cancer 1992, 28, 372-377.
65. Masaki, T.; Igarashi, K.; Tokuda, M.; Yukimasa, S.; Han, F.; Jin, Y. J.; Li, J. Q.; Yoneyama, H.; Uchida, N.; Fujita, J.; Yoshiji, H.; Watanabe, S.; Kurokohchi, K.; Kuriyama, S. pp60c-src activation in lung adenocarcinoma. Eur. J. Cancer 2003, 39, 1447-1455.
66. Bolen, J. B.; Veillette, A.; Schwartz, A. M.; DeSeau, V.; Rosen, N. Analysis of pp60c-src in human colon carcinoma and normal human colon mucosal cells. Oncogene Res. 1987, 1, 149-168.
67. Cartwright, C. A.; Kamps, M. P.; Meisler, A. I.; Pipas, J. M.; Eckhart, W. pp60c-src activation in human colon carcinoma. J. Clin. Invest. 1989, 83, 2025-2033.
68. Ito, Y.; Kawakatsu, H.; Takeda, T.; Tani, N.; Kawaguchi, N.; Noguchi, S.; Sakai, T.; Matsuura, N. Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma. Breast Cancer Res. Treat. 2002, 76, 261-267.
69. Zou, D.; Yoon, H. S.; Anjomshoaa, A.; Perez, D.; Fukuzawa, R.; Guilford, P.; Humar, B. Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Res. 2009, 11, R45. http://breast-cancer-research.com/content/11/4/R45
70. Lutz, M. P.; Esser, I. B.; Flossmann-Kast, B. B.; Vogelmann, R.; Luhrs, H.; Friess, H.; Buchler, M. W.; Adler, G. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. 1998, 243, 503-508.
71. Talamonti, M. S.; Roh, M. S.; Curley, S. A.; Gallick, G. E. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J. Clin. Invest. 1993, 91, 53-60.
72. Termuhlen, P. M.; Curley, S. A.; Talamonti, M. S.; Saboorian, M. H.; Gallick, G. E. Site-specific differences in pp60c-src activity in human colorectal metastases. J. Surg. Res. 1993, 54, 293-298.
73. Aligayer, H.; Boyd, D. D.; Heiss, M. M.; Abdalla, E. K.; Curley, S. A.; Gallick, G. E. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002, 94, 344-351.
74. Campbell, E. J.; McDuff, E.; Tatarov, O.; Tovey, S.; Brunton, V.; Cooke, T. G.; Edwards, J. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br. J. Cancer 2008, 99, 1769-1774.
75. Oneyama, C.; Nakano, H.; Sharma, S. V. UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug. Oncogene 2002, 21, 2037-2050.
76. Sharma, S. V.; Oneyama, C.; Yamashita, Y.; Nakano, H.; Sugawara, K.; Hamada, M.; Kosaka, N.; Tamaoki, T. UCS15A, a nonkinase inhibitor of Src signal transduction. Oncogene 2001, 20, 2068-2079.
77. Shakespeare, W.; Yang, M.; Bohacek, R.; Cerasoli, F.; Stebbins, K.; Sundaramoorthi, R.; Azimioara, M.; Vu, C.; Pradeepan, S.; Metcalf, C. III.; Haraldson, C.; Merry, T.; Dalgarno, D.; Narula, S.; Hatada, M.; Lu, X.; van Schravendijk, M. R.; Adams, S.; Violette, S.; Smith, J.; Guan, W.; Bartlett, C.; Herson, J.; Iuliucci, J.; Weigele, M.; Sawyer, T. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl. Acad. Sci. USA 2000, 97, 9373-9378.
78. Lau, G. M.; Lau, G. M.; Yu, G. L.; Gelman, I. H.; Gutowski, A.; Hangauer, D.; Fang, J. W. Expression of Src and FAK in hepato-cellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig. Dis. Sci. 2009, 54, 1465-1474.
79. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M. L.; Wityak, J.; Borzilleri, R. M. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004, 47, 6658-6661.
80. Chang, Q.; Jorgensen, C.; Pawson, T.; Hedley, D. W. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and down-stream signalling in pancreatic cancer. Br. J. Cancer 2008, 99, 1074-1082.
81. Brave, M.; Goodman, V.; Kaminskas, E.; Farrell, A.; Timmer, W.; Pope, S.; Harapanhalli, R.; Saber, H.; Morse, D.; Bullock, J.; Men, A.; Noory, C.; Ramchandani, R.; Kenna, L.; Booth, B.; Gobburu, J.; Jiang, X.; Sridhara, R.; Justice, R.; Pazdur, R. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin. Cancer Res. 2008, 14, 352-359.
82. Nam, S.; Kim, D.; Cheng, J. Q.; Zhang, S.; Lee, J. H.; Buettner, R.; Mirosevich, J.; Lee, F. Y.; Jove, R. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005, 65, 9185-9189.
83. Serrels, A.; Macpherson, I. R.; Evans, T. R.; Lee, F. Y.; Clark, E. A.; Sansom, O. J.; Ashton, G. H.; Frame, M. C.; Brunton, V. G. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol. Cancer Ther. 2006, 5, 3014-3022.
84. Finn, R. S.; Dering, J.; Ginther, C.; Wilson, C. A.; Glaspy, P.; Tchekmedyian, N.; Slamon, D. J. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative breast cancer cell lines growing in vitro. Breast Cancer Res. Treat. 2007, 105, 319-326.
85. Huang, F.; Reeves, K.; Han, X.; Fairchild, C.; Platero, S.; Wong, T. W.; Lee, F.; Shaw, P.; Clark, E. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007, 67, 2226-2238.
86. Nautiyal, J.; Majumder, P.; Patel, B. B.; Lee, F. Y.; Majumdar, A. P. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett. 2009, 283, 143-151.
87. Shor, A. C.; Keschman, E. A.; Lee, F. Y.; Muro-Cacho, C.; Letson, G. D.; Trent, J. C.; Pledger, W. J.; Jove, R. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 2007, 67, 2800-2808.
88. Song, L.; Morris, M.; Bagui, T.; Lee, F. Y.; Jove, R.; Haura, E. B. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006, 66, 5542-5548.
89. Yano, A.; Tsutsumi, S.; Soga, S.; Lee, M. J.; Trepel, J.; Osada, H.; Neckers, L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc. Natl. Acad. Sci. USA 2008, 105, 15541-15546.
90. Koreckij, T.; Nguyen, H.; Brown, L. G.; Yu, E. Y.; Vessella, R. L.; Corey, E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br. J. Cancer 2009,101, 263-268.
91. Vandyke, K.; Dewar, A. L.; Farrugia, A. N.; Fitter, S.; Bik, T. L.; Hughes, T. P.; Zannettino, A. C. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009, 23, 994-997.
92. Brownlow, N.; Mol, C.; Hayford, C.; Ghaem-Maghami, S.; Dibb, N. J. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2009, 23, 590-594.
93. Green, T. P.; Fennell, M.; Whittaker, R.; Curwen, J.; Jacobs, V.; Allen, J.; Logie, A.; Hargreaves, J.; Hickinson, D. M.; Wilkinson, R. W.; Elvin, P.; Boyer, B.; Carragher, N.; Ple, P. A.; Bermingham, A.; Holdgate, G. A.; Ward, W. H.; Hennequin, L. F.; Davies, B. R.; Costello, G. F. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol. Oncol. 2009, 3, 248-261.
94. Hiscox, S.; Morgan, L.; Green, T. P.; Barrow, D.; Gee, J.; Nicholson, R. I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 2006, 97, 263-274.
95. Chang, Y. M.; Bai, L.; Liu, S.; Yang, J. C.; Kung, H. J.; Evans, C. P. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008, 27, 6365-6375.
96. Yang, J. C.; Ok, J. H.; Busby, J. E.; Borowsky, A. D.; Kung, H. J.; Evans, C. P. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res. 2009, 69, 151-160.
97. de Vries, T. J.; Mullender, M. G.; van Duin, M. A.; Semeins, C. M.; James, N.; Green, T. P.; Everts, V.; Klein-Nulend, J. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol. Cancer Res. 2009, 7, 476-488.
98. Puttini, M.; Coluccia, A. M.; Boschelli, F.; Cleris, L.; Marchesi, E.; Donella-Deana, A.; Ahmed, S.; Redaelli, S.; Piazza, R.; Magistroni, V.; Andreoni, F.; Scapozza, L.; Formelli, F.; Gambacorti-Passerini, C. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006, 66, 11314-11322.
99. Coluccia, A. M.; Benati, D.; Dekhil, H.; De Filippo, A.; Lan, C.; Gambacorti-Passerini, C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006, 66, 2279-2286.
100. Zhang, J.; Kalyankrishna, S.; Wislez, M.; Thilaganathan, N.; Saigal, B.; Wei, W.; Ma, L.; Wistuba, I. I.; Johnson, F. M.; Kurie, J. M. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am. J. Pathol. 2007, 170, 366-376.
101. Golas, J. M.; Lucas, J.; Etienne, C.; Golas, J.; Discafani, C.; Sridharan, L.; Boghaert, E.; Arndt, K.; Ye, F.; Boschelli, D. H.; Li, F.; Titsch, C.; Huselton, C.; Chaudhary, I.; Boschelli, F. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 2005, 65, 5358-5364.
102. Yu, E. Y.; Wilding, G.; Posadas, E.; Gross, M.; Culine, S.; Massard, C.; Morris, M. J.; Hudes, G.; Calabro, F.; Cheng, S.; Trudel, G. C.; Paliwal, P.; Sternberg, C. N. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2009, 15, 7421-7428.
103. Lara, P. N., Jr.; Longmate, J.; Evans, C. P.; Quinn, D. I.; Twardowski, P.; Chatta, G.; Posadas, E.; Stadler, W.; Gandara, D. R. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009, 20, 179-184.
104. Mendiratta, P.; Mostaghel, E.; Guinney, J.; Tewari, A. K.; Porrello, A.; Barry, W. T.; Nelson, P. S.; Febbo, P. G. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J. Clin. Oncol. 2009, 27, 2022-2029.
105. Jones, R. J.; Young, O.; Renshaw, L.; Jacobs, V.; Fennell, M.; Marshall, A.; Green, T. P.; Elvin, P.; Womack, C.; Clack, G.; Dixon, J. M. Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Res. Treat. 2009, 114, 211-221.
106. Bild, A. H.; Parker, J. S.; Gustafson, A. M.; Acharya, C. R.; Hoadley, K. A.; Anders, C.; Marcom, P. K.; Carey, L. A.; Potti, A.; Nevins, J. R.; Perou, C. M. An integration of complementary strategies for gene expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res. 2009, 11, R55. http://breast-cancer-research.com/content/11/4/R55
107. Palacios, E. H.; Weiss, A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004, 23, 7990-8000.
108. Schade, A. E.; Schieven, G. L.; Townsend, R.; Jankowska, A. M.; Susulic, V.; Zhang, R.; Szpurka, H.; Maciejewski, J. P. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008, 111, 1366-1377.
109. Weichsel, R.; Dix, C.; Wooldridge, L.; Clement, M.; Fenton-May, A.; Sewell, A. K.; Zezula, J.; Greiner, E.; Gostick, E.; Price, D. A.; Einsele, H.; Seggewiss, R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin. Cancer Res. 2008, 14, 2484-2491.
110. Sillaber, C.; Herrmann, H.; Bennett, K.; Rix, U.; Baumgartner, C.; Bohm, A.; Herndlhofer, S.; Tschachler, E.; Superti-Furga, G.; Jager, U.; Valent, P. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur. J. Clin. Invest. 2009, 39, 1098-1109.
111. Mustjoki, S.; Ekblom, M.; Arstila, T. P.; Dybedal, I.; Epling-Burnette, P. K.; Guilhot, F.; Hjorth-Hansen, H.; Hoglund, M.; Kovanen, P.; Laurinolli, T.; Liesveld, J.; Paquette, R.; Pinilla-Ibarz, J.; Rauhala, A.; Shah, N.; Simonsson, B.; Sinisalo, M.; Steegmann, J. L.; Stenke, L.; Porkka, K. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009, 23, 1398-1405.
112. Kim, D. H.; Kamel-Reid, S.; Chang, H.; Sutherland, R.; Jung, C. W.; Kim, H. J.; Lee, J. J.; Lipton, J. H. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009, 94, 135-139.